Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 7Neurofibroma, Plexiform 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 2Recurrence 1Pain 1Neoplasms 1Neoplasm Metastasis 1Muscle Invasive Bladder Cancer 1Melanoma 1Gallbladder Neoplasms 1Astrocytoma 1Advanced Non Small Cell Lung Cancer 1

Interventions

Temozolomide 7Radiotherapy 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Radiation 4Radiotherapy, Intensity-Modulated 2Nivolumab 2vorasidenib 1veliparib 1trametinib 1tocilizumab 1pembrolizumab 1fimepinostat 1dabrafenib 1atezolizumab 1abemaciclib 1Vorinostat 1Vincristine 1Spinal Puncture 1Radiotherapy, Conformal 1Protons 1Proton Therapy 1Procarbazine 1OKN 007 1Mycophenolic Acid 1Lomustine 1Irinotecan 1Ipilimumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Astrocytoma × AZD 6244 × Clear all
NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
217 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡